Harmony Biosciences Holdings, Inc. (HRMY) stock
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Earnings
Harmony Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Harmony Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026before the open | $268.90M | +12.3% | $0.81 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 16, 2026before the open | $261.00M | +30.2% | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $215.40M | +16.6% | $0.55 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | $243.80M | +21.1% | $0.38 | $0.57 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $239.50M | +28.8% | $0.87 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $200.50M | +16.0% | $0.68 | $0.92 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025before the open | $184.70M | +19.5% | $0.78 | $1.03 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025before the open | $201.30M | +19.5% | $0.85 | $1.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024before the open | $186.00M | +16.0% | $0.79 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $172.80M | +28.8% | $0.20 | $1.05 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 30, 2024before the open | $154.60M | +29.8% | – | $0.88 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $168.40M | +31.3% | $0.45 | $0.73 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 31, 2023before the open | $160.30M | +36.8% | $0.63 | $0.97 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023before the open | $134.20M | +25.4% | $0.56 | $0.76 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023before the open | $119.10M | +39.6% | $0.48 | $0.66 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023before the open | $128.30M | +40.7% | $0.79 | $1.01 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 1, 2022before the open | $117.20M | +45.2% | $1.44 | $0.95 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022before the open | $107.00M | – | $0.39 | $0.57 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022before the open | $85.30M | – | $0.35 | $0.51 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022before the open | $91.20M | – | $0.38 | $0.63 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021before the open | $80.70M | – | -$0.17 | $0.51 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 11, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 25, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Harmony Biosciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| net product revenue | FY2026 | $1.00B – $1.04B | $1.00B – $1.04B | Reaffirmed | Jul 16, 2026 |
| net revenue | FY2026 | $1.00B – $1.04B | $1.00B – $1.04B | Reaffirmed | Nov 4, 2026 |
Guidance vs results
The last range Harmony Biosciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $845.00M – $865.00M | $868.50MΣ4Q | Above range |
Guidance history
Every forecast Harmony Biosciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | net revenue | FY2026 | $1.00B – $1.04B | Reaffirmed |
| Jul 16, 2026 | net product revenue | FY2026 | $1.00B – $1.04B | Reaffirmed |
| May 7, 2026 | Net revenue | FY2026 | $1.00B – $1.04B | Reaffirmed |
| Feb 24, 2026 | Net revenue | FY2026 | $1.00B – $1.04B | New |
| Jan 12, 2026 | Net revenue | FY2026 | $1.00B – $1.04B | New |
| Nov 4, 2025 | net product revenue | FY2025 | $845.00M – $865.00M | Raised |
| Oct 23, 2025 | revenue guidance | FY2025 | $845.00M – $865.00M | New |
| Aug 5, 2025 | net product revenue | FY2025 | $820.00M – $860.00M | Reaffirmed |
| May 6, 2025 | net product revenue | FY2025 | $820.00M – $860.00M | Reaffirmed |
| Feb 25, 2025 | net product revenue | FY2025 | $820.00M – $860.00M | Reaffirmed |
| Jan 13, 2025 | Net revenue | FY2025 | $820.00M – $860.00M | New |
| Oct 29, 2024 | net product revenue | FY2024 | $700.00M – $720.00M | Reaffirmed |
| Aug 6, 2024 | net product revenue | FY2024 | $700.00M – $720.00M | Reaffirmed |
| Apr 30, 2024 | net product revenue | FY2024 | $700.00M – $720.00M | New |
| Feb 22, 2024 | net product revenue | FY2024 | $700.00M – $720.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Harmony Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?